N4 Pharma updates on patent filing

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its patent application for Nuvec®, filed in March 2020 (no. PCT/GB2021/050960 Gene Therapy Vectors).

The Company originally filed a Patent Cooperation Treaty (“PCT”) patent application for Nuvec® to be used to manufacture viral vectors and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments. Under the terms of the PCT application process and following feedback from an international patent search, the Company is now making enhancements to the claims of the applications in the territories in which it wishes to gain patent protection. N4 pharma is pursuing this patent application which, if granted, would be in addition to the patents it has exclusively licensed from the University of Queensland.

The Company has decided to focus its claims on the use of the specific spiky properties of Nuvec™ to load and transfect viral vectors, especially adenoviral vectors and lentiviral vectors. This is based on feedback from the examiner and further work the Company has done that has shown how combining Nuvec® with adenoviral vectors (in addition to its earlier work on lentiviral vectors) can lead to an improvement in vector performance and a reduction in the amount of the viral vector needed.

The Company has filed ongoing patent applications in the following territories: Europe (including UK); USA; Japan; India and Canada. It will also file applications in Australia and China in due course. 

Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:

“We are seeking to refine our claims to give this patent the greatest chance of being granted in a field with strong commercial opportunity. Should the patent be granted in these territories it would mirror the regions granted for the main patent which the Company has licensed from the University of Queensland and further strengthen the commercial protection of Nuvec®.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma well funded to deliver its siRNA programme

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December 2022. Highlights: • Nuvec® as a delivery system

    N4 Pharma

    N4 Pharma AGM to be held on 3 April 2023

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that its Annual Report and Accounts for the year ended 31 December 2022 and Notice of its

    N4 Pharma

    N4 Pharma greatly encouraged by the oral delivery of Nuvec results

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the

    N4 Pharma

    N4 Pharma Broker Offer to raise a maximum of £1 million

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an opportunity for shareholders and other investors who did not participate in the fundraising announced today to

    N4 Pharma

    N4 Pharma raises £1million through a placing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £1 million (before expenses) through a placing of 50,000,000 new ordinary shares of

    N4 Pharma

    N4 Pharma successful Nuvec double siRNA testing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced successful in vitro testing of Nuvec® loaded with two small interfering RNA (siRNA) probes. On 14 September 2022, the Company

    N4 Pharma

    N4 Pharma continue to make excellent progress

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30 June 2022. Highlights: ·      Exciting opportunities identified for

    N4 Pharma

    N4 Pharma plans for commercialising Nuvec (VIDEO)

    N4 Pharma plc (LON:N4P) CEO Nigel Theobald chats to DirectorsTalk Interviews about its development plans for commercialising Nuvec. Nigel talks us through the update highlights, explains why companies working with siRNA are much more open to using novel delivery

    N4 Pharma

    N4 Pharma’s proof of concept work is extremely encouraging

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced an update on its current work programmes. Highlights: ·      Medicines Discovery Catapult study shows demonstrable suppression of tumour

    N4 Pharma

    N4 Pharma AGM to be held on 24 March 2022

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended 31 December 2021, together with the notice of

    No more posts to show